Cambridge-based biopharmaceutical company Sage Therapeutics filed a lawsuit against their partner, the biotechnology company ...

Biogen’s disappointing Leqembi performance and weak pipeline hurt future growth. Learn why BIIB stock is rated "sell" due to ...

In exchange for $165 million, Biogen now has access to zorevunersen, a potential first-of-its-kind treatment for Dravet ...

Sage Therapeutics’ board of directors has turned back partner Biogen’s opportunitistic attempt at a takeover, unanimously rejecting a $469 million offer from Biogen it said “significantly ...

Sage Therapeutics has rejected Biogen’s $469m takeover offer, with its board of directors unanimously concluding that the bid “significantly undervalues” the company. Made earlier this year ...

Biogen Inc. CEO Christopher Viehbacher gave investors an overview of what type of deals the company is looking for Wednesday ...

Biogen has bolstered its pipeline by licensing ex-US rights to a drug for Dravet syndrome – a rare form of epilepsy – from ...

After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on a range of strategic options. However, the company's board of directors ...

Jan 27 (Reuters) - Sage Therapeutics (SAGE.O), opens new tab said on Monday that its board has unanimously rejected Biogen’s (BIIB.O), opens new tab $469 million offer, stating it "significantly ...

Last year, the first phase 3 trial of Sage Therapeutics and Biogen's antidepressant hopeful zuranolone hit its efficacy targets, but raised doubts about the durability of the response. Now ...